Hypertension in pregnancy contributes substantially to perinatal mortality and morbidity of both the mother and her child. High blood pressure is mainly responsible for this adverse outcome, in particular when associated with preeclampsia. Although preeclampsia is nowadays a well-known clinical-obstetrical entity, and screening for this complication has been part of routine care during pregnancy for nearly 100 years, its cause is still enigmatic.
INTRODUCTION
Hypertension and its different clinical manifestations during pregnancy is one of the most frequent and gradually increasing complications during pregnancy. Indeed, a rising prevalence from 6.7 to 8.3% has been recently reported from the United States in the years 1998-2006 [1] . During this time period, the prevalence of chronic hypertension has increased by 50% (from 1.1 to 1.7%), and that of severe preeclampsia/eclampsia by 30% (from 0.9 to 1.2%). Of note, 9.4% of the pregnancy-related maternal deaths in the United States from 2006 to 2010 were associated with hypertension, and 94.6% of those deaths were due to complications associated with preeclampsia/eclampsia [2] . Similar findings have been reported by the Center for Maternal and Child Enquiries for the years 2006-2008 [3] . In the United Kingdom, preeclampsia is still the second most frequent cause for pregnancy-associated maternal mortality. Hypertensive disorders also carry a risk for the baby. In the most recent UK perinatal mortality report, one in 20 (5%) stillbirths in fetuses without congenital abnormality occurred in women with preeclampsia. The contribution of preeclampsia to the overall preterm birth rate is substantial; 8-10% of all preterm births result from hypertensive disorders. Half of women with severe preeclampsia give preterm birth [3] .
New insights relevant to diagnosis, classification, and management of hypertensive complications in pregnancy in the last years have prompted a plethora of guidelines from different national and international societies. Due to its syndromal manifestation, there is -as expectedno definite consensus on the classification of preeclampsia. Indeed, there is a dispute on whether proteinuria should be kept or placental insufficiency should be added as a characteristic defining preeclampsia [4 && ,5 && ,6-8,9
the pathophysiology of preeclampsia has led to considerations that the traditional clinically based definition may be replaced by one involving angiogenic factors and other biomarkers [10,11 && ]. For decades preeclampsia was thought to be a consequence of placental ischemia due to insufficient perfusion of the intervillous space. The factors that induce placental hypoxia are complex and closely related to the trophoblastic invasion and spiral artery remodeling, fundamental pathways for the adequate development and functioning of the placenta. Necrotic placental products released directly into the maternal circulation together with a genetic, vascular, and/or preexisting metabolic susceptibility lead to this generalized endothelial dysfunction, which is responsible for the clinical signs of preeclampsia. Recently, a concept of an angiogenic imbalance has been postulated, which may help to properly define preeclampsia and in addition to distinguish it from other hypertensive disorders arising during pregnancy [11 && ]. Moreover, tests assessing maternal serum levels of biochemical factors may also be useful for screening purposes, as there is some evidence that early interventions in women at risk may reduce the prevalence of preeclampsia [12] [13] [14] [15] .
Management is still limited to control hypertension and to prevent maternal complications such as stroke, brain hemorrhage, and pulmonary edema. Administration of magnesium sulfate, in particular in severe preeclampsia, effectively reduces the risk of eclampsia, and timely delivery is still the only causal therapy of preeclampsia. However, in early-onset preeclampsia, that is, showing clinical signs before 34 weeks of gestation, expectant management may reduce fetal mortality and morbidity. Steroid administration to enhance lung maturation and careful fetal and maternal assessment are mandatory, whereas delivery is expedited in case of suspected deterioration [16] .
DEFINITIONS AND CLASSIFICATIONS
Women with preexisting medical conditions such as chronic hypertension, as well as renal, immunological, and/or metabolic disorders are at increased risk for adverse outcome during pregnancy and in particular for the development of preeclampsia. However, hypertension or preeclampsia may also complicate the pregnancy course of women without specific risk factors. In both situations, the classical manifestation of preeclampsia -an exclusively pregnancy-associated diagnosis -requires the presence of hypertension and proteinuria after 20 weeks of gestation. However, the presence of proteinuria is no longer an essential requirement for the diagnosis. Indeed, hypertension in combination with clinical signs of systemic involvement such as hematological (thrombocytopenia), renal (insufficiency), hepatic (elevated liver transaminases), or pulmonary (lung edema) features or cerebral symptoms also define preeclampsia. Moreover, placental insufficiency with intrauterine growth restriction is, in some [4 && ,5 && ,9 & ] but not all societies, also part of this preeclamptic syndrome (Table 1) .
KEY POINTS
Hypertensive complications occurring during pregnancy are still a leading cause of perinatal mortality for both the mother and her child worldwide.
Preexisting medical complications are associated with adverse pregnancy outcome mainly due to a higher risk to develop superimposed preeclampsia.
Gestational hypertension and in particular early-onset or severe preeclampsia are sentinel signs of an underlining endothelial dysfunction that places mother and child at higher risk for vascular insults later in life.
The aim to treat hypertension is to lower the risk of cardiovascular complications such as stroke during pregnancy. Gestational hypertension is defined as blood pressure of 140/90 mmHg or higher in a previously normotensive woman. If hypertension is present at less than 20 weeks of gestation, chronic or preexisting hypertension has to be postulated. However, it is important to have documented a normal blood pressure either before conception or at least in early pregnancy as -due to gestational physiology -the blood pressure decreases in the first half of pregnancy, reaching its nadir by mid-pregnancy. A normal first blood pressure between 16 and 20 weeks may, therefore, result in a missed diagnosis of chronic hypertension [4 && ,18] . Similarly, chronic hypertension has to be differentiated from the disorder of white coat hypertension (Table 1) . Ideally, the diagnosis is confirmed by demonstrating normal blood pressure using 24 h ambulatory blood pressure monitoring (ABPM) [19] . If white coat hypertension is confirmed, antihypertensives can be avoided, and the pregnant woman can be monitored by regular home blood pressure assessments. This is important as the risk of gestational hypertension or preeclampsia in women with white coat hypertension, and in particular in those women in whom hypertension has been confirmed by ABPM, is substantially increased. Moreover, ABPM allows the diagnosis of nocturnal hypertension, which has also been associated with a higher risk of maternal and fetal complications [17] . The European Society of Hypertension has recently provided reference ranges for AMBP according to gestational age, which are depicted in Table 2 [17] .
As mentioned above, preeclampsia (and preeclampsia superimposed on chronic hypertension) is defined as hypertension and the coexistence of at least one of the conditions summarized in Table 1 [4 && ,11 && ]. The gold standard for diagnosing abnormal proteinuria is the detection of at least 300 mg protein in a 24-h urinary sample. In practice, this method is often replaced by the measurement of a spot urine protein/creatinine ratio (!30 mg/mmol), or dipstick testing, which still provides a reasonable assessment of proteinuria; in particular if at least 2þ (>1 g/l). However, the degree of proteinuria provides little additional information on the severity of preeclampsia [20] . Signs of maternal organ dysfunction may be renal insufficiency (creatinine !90 mmol/l), liver involvement with elevated transaminases (!twice upper limit of normal) and/or right upper quadrant or epigastric abdominal pain, neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia/clonus AE severe headache, visual scotomata), and hematological complications (platelet count <150 000/dl, disseminated intravascular coagulation, hemolysis). Preeclampsia can also be classified according to its severity ( Table 3 ) or according to gestational age at diagnosis or delivery (Table 4 ). Whereas the severitybased classification may help in the management of preeclampsia, the gestational age-based classification implies that preeclampsia may indeed have several subtypes with different pathophysiologic pathways and long-term consequences. Indeed, cardiovascular complications of the mother and offspring are mostly associated with the early and severe forms of preeclampsia [22, 23] .
TREATMENT OF HYPERTENSION IN PREGNANCY
The primary aim of treating hypertension in pregnancy is to reduce maternal complications without increasing those of the fetus. This is particularly true when SBP and DBP rise above 160 or 110 mmHg, respectively. At these levels the risk of intracranial hemorrhage or stroke is high. In cases of moderate hypertension, lowering blood pressure may be associated with poor placental perfusion. Similarly, for patients with chronic hypertension prior to conception, antihypertensive medications are not recommended until high blood pressure levels are noted, that is, SBP 150-160 mmHg or DBP 100-110 mmHg, as the risk of intrauterine growth restriction is increased. Therefore, discontinuation of antihypertensive medication under intensified home blood pressure monitoring may be an option in these cases. The goals of treating hypertension during pregnancy among the different societies and guidelines are similar: prevention of severe hypertension, progressive renal failure, or other cardiovascular complications [18] . Importantly, in chronic hypertension women should ideally be evaluated prior to conception to assess its severity, possible secondary causes, and presence of targetorgan dysfunction [4 && ,5 && , 6-8,9 & ,24]. Moreover, in women taking antihypertensive medication and planning to become pregnant it may be prudent to carefully evaluate the medication and possibly switch to those medicaments known to be well tolerated in pregnancy (Table 5 ). This is particularly true for angiotensin converting enzyme inhibitors and angiotensin receptor blockers, which have been associated with fetal toxicity [8, 24] . 26] . Some concerns exist about the safety of blood pressure treatment during pregnancy. Indeed, a relationship between treatment-induced fall in mean arterial pressure and the prevalence of small-for-gestational-age infants has been found independently of the type of hypertension, type of antihypertensive agent used, and duration of therapy [25 & ]. A recently published randomized controlled study including pregnant women with nonsevere chronic or gestational hypertension and investigating the maternal and fetal effect of less-tight blood pressure control (target DBP of 100 mmHg) versus tight control (target DBP of 85 mmHg) showed that tight control of hypertension conferred no benefit to the fetus and had only marginal effect for the mother (less severe hypertension) [26] . However, this study also gives some reassurance that the applied tight control does not harm the child [27] .
CONCLUSION
This review intends to highlight the clinical aspects of various classifications proposed by different obstetric societies, which will also affect the management of hypertensive disorders of pregnancy. Regarding their definitions and management, no obstetric society has yet implemented angiogenetic criteria, although a huge scientific effort has already been undertaken. Future research addressing the proangiogenetic and antiangiogenetic profiles of hypertensive pregnancy disorders is eagerly awaited.
